NMPA approves U.S. pharmaceutical company Vimizim (elosulfase alfa) for treatment of MPS IVA
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
MPS IVA is caused by the inactivity of an enzyme involved in the metabolism of glycomine polysaccharides (GAG)The gradual accumulation of GAGs can cause severe lesions and multi-system clinical damage, leading to a decrease in the patient's functional capacity and quality of life, as well as early deathThe most common characteristics of MPS IVA are poor bone development, musculoskeletal or respiratory dysfunction that requires frequent surgical treatment and severely limit stoic mobility, endurance, and respiratory functionrecently, vimizim (elosulfase alfa), a subsidiary of(http://, apharmaceutical(http://company, was approved by the NationalMedicines(http://Regulatory Authority (NMPA) for the treatment of rare diseases of polysaccharide polysaccharide ivaIVA (MAMA) (Morsua syndrome)About Vimzim
Vimzim is the onlydrug(http://approved worldwide for the treatment of MPS IVA, an extremely rare genetic lysosome setic disorder affecting approximately 3,000 people in developed countriesVimizim is the first approved enzyme replacement therapy (ERT) that targets the basic cause of MPS IVA, N-acetyl semilachylamine-6 sulphatease (GALNS) deficiencydata from the clinicaltrial(http://in, the drug improves lung function and significantly increases walking distanceThe sales team of the phenylketonuretic urea drug dihydroxinate (Kuvan) in China will be responsible for promoting the drug in the Chinese market
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
